Nvelop Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Nvelop Therapeutics was a Boston-area drug delivery biotech formed in 2022 and publicly launched in April 2024, led by CEO Jeff Walsh, the former chief strategy officer of bluebird bio. It developed non-viral, programmable delivery technology to carry DNA-modifying machinery to precise tissues in the body for in vivo genetic medicines. On December 11, 2024, it merged with fellow gene-editing startup Chroma Medicine to launch nChroma Bio — combining Chroma's epigenetic editing 'cargo' with Nvelop's delivery vehicles — alongside an oversubscribed $75 million financing round led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture, and Newpath Partners. The merger involved layoffs on both sides; Jeff Walsh became CEO and Jeff Marrazzo chairman of the combined company, whose lead program is CRMA-1001, a liver-targeted epigenetic editing therapy for chronic hepatitis B and D.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Formed
Nvelop Therapeutics was formed as a drug delivery biotech developing in vivo targeted delivery technology for genetic medicines.
- Public launch
In April 2024, Nvelop publicly launched with CEO Jeff Walsh (former bluebird bio chief strategy officer) at the helm.
- Merged into nChroma Bio
On December 11, 2024, Nvelop merged with Chroma Medicine to launch nChroma Bio, with an oversubscribed $75 million financing and layoffs on both sides.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.